The addition to the standard therapy of Nimotuzumab®, a humanized therapeutic monoclonal antibody against EGFR, yielded, on the other hand, positive results only in a post hoc analysis where it revealed an improvement in survival in patients with residual tumor and nonmethylated MGMT (PFS 6.2 vs. 4 months; OS 19 vs. 13.8 months). Here, EGFR is linked to neoplasm.